TSHA vs. NRIX, VIR, SNDX, ARVN, ANIP, DAWN, ADPT, RCUS, CALT, and SYRE
Should you be buying Taysha Gene Therapies stock or one of its competitors? The main competitors of Taysha Gene Therapies include Nurix Therapeutics (NRIX), Vir Biotechnology (VIR), Syndax Pharmaceuticals (SNDX), Arvinas (ARVN), ANI Pharmaceuticals (ANIP), Day One Biopharmaceuticals (DAWN), Adaptive Biotechnologies (ADPT), Arcus Biosciences (RCUS), Calliditas Therapeutics AB (publ) (CALT), and Spyre Therapeutics (SYRE). These companies are all part of the "pharmaceutical products" industry.
Taysha Gene Therapies vs.
Nurix Therapeutics (NASDAQ:NRIX) and Taysha Gene Therapies (NASDAQ:TSHA) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their community ranking, valuation, dividends, institutional ownership, risk, media sentiment, profitability, analyst recommendations and earnings.
In the previous week, Taysha Gene Therapies had 2 more articles in the media than Nurix Therapeutics. MarketBeat recorded 4 mentions for Taysha Gene Therapies and 2 mentions for Nurix Therapeutics. Taysha Gene Therapies' average media sentiment score of 0.41 beat Nurix Therapeutics' score of 0.00 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.
Nurix Therapeutics presently has a consensus price target of $31.81, suggesting a potential upside of 88.57%. Taysha Gene Therapies has a consensus price target of $6.63, suggesting a potential upside of 311.49%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts clearly believe Taysha Gene Therapies is more favorable than Nurix Therapeutics.
Taysha Gene Therapies has lower revenue, but higher earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.
77.7% of Taysha Gene Therapies shares are owned by institutional investors. 7.2% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 2.7% of Taysha Gene Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Taysha Gene Therapies has a net margin of -229.67% compared to Nurix Therapeutics' net margin of -354.85%. Nurix Therapeutics' return on equity of -53.65% beat Taysha Gene Therapies' return on equity.
Nurix Therapeutics has a beta of 2.14, meaning that its share price is 114% more volatile than the S&P 500. Comparatively, Taysha Gene Therapies has a beta of 0.92, meaning that its share price is 8% less volatile than the S&P 500.
Taysha Gene Therapies received 24 more outperform votes than Nurix Therapeutics when rated by MarketBeat users. However, 79.41% of users gave Nurix Therapeutics an outperform vote while only 77.21% of users gave Taysha Gene Therapies an outperform vote.
Summary
Taysha Gene Therapies beats Nurix Therapeutics on 10 of the 18 factors compared between the two stocks.
Get Taysha Gene Therapies News Delivered to You Automatically
Sign up to receive the latest news and ratings for TSHA and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Taysha Gene Therapies Competitors List
Related Companies and Tools
This page (NASDAQ:TSHA) was last updated on 2/21/2025 by MarketBeat.com Staff
